A Study of LY4175408 in Participants With Advanced Cancer
Recruiting · Phase 1 · NCT07046923
Conditions: Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis, Triple Negative Breast Cancer
At a glance
- Research payments reported, 2025
- $265,857
- U.S. investigators named
- 2
- Sites paid
- 1
- Planned or actual enrollment
- 240
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY4175408 (drug), Pembrolizumab (drug), Carboplatin (drug), Cisplatin (drug)
- Dates
- Started 2025-07-28; completion 2030-07
- Results posted
- Not yet
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.
From ClinicalTrials.gov, last updated 2026-06-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $265,857 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Manish R. Patel, MD Medical Oncology · Sarasota, FL
- Cesar A. Perez Batista, M.D. Medical Oncology · Orlando, FL
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Florida Cancer Specialists $265,857
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.